TWI286933B - Method of treating neurodegenerative disorders of the retina and optic nerve head - Google Patents

Method of treating neurodegenerative disorders of the retina and optic nerve head Download PDF

Info

Publication number
TWI286933B
TWI286933B TW090119751A TW90119751A TWI286933B TW I286933 B TWI286933 B TW I286933B TW 090119751 A TW090119751 A TW 090119751A TW 90119751 A TW90119751 A TW 90119751A TW I286933 B TWI286933 B TW I286933B
Authority
TW
Taiwan
Prior art keywords
substituted
aryl
branched alkyl
derivative
heterocyclic group
Prior art date
Application number
TW090119751A
Other languages
English (en)
Chinese (zh)
Inventor
Daniel A Gamache
Gustav Graff
John M Yanni
Michael A Kapin
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Application granted granted Critical
Publication of TWI286933B publication Critical patent/TWI286933B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW090119751A 2000-08-14 2001-08-13 Method of treating neurodegenerative disorders of the retina and optic nerve head TWI286933B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22513200P 2000-08-14 2000-08-14

Publications (1)

Publication Number Publication Date
TWI286933B true TWI286933B (en) 2007-09-21

Family

ID=22843666

Family Applications (1)

Application Number Title Priority Date Filing Date
TW090119751A TWI286933B (en) 2000-08-14 2001-08-13 Method of treating neurodegenerative disorders of the retina and optic nerve head

Country Status (17)

Country Link
US (1) US6638976B2 (fr)
EP (1) EP1309322B1 (fr)
JP (1) JP2004506010A (fr)
AR (1) AR030346A1 (fr)
AT (1) ATE330596T1 (fr)
AU (1) AU8125801A (fr)
BR (1) BR0113201A (fr)
CA (1) CA2418059C (fr)
CY (1) CY1106155T1 (fr)
DE (1) DE60120990T2 (fr)
DK (1) DK1309322T3 (fr)
ES (1) ES2266229T3 (fr)
HK (1) HK1057332A1 (fr)
MX (1) MXPA03001160A (fr)
PT (1) PT1309322E (fr)
TW (1) TWI286933B (fr)
WO (1) WO2002013805A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132773A1 (en) * 2001-08-13 2004-07-08 Gamache Daniel A Method of treating neurodgenerative disorders of the retina and optic nerve head
CA2527121A1 (fr) * 2003-06-13 2004-12-29 Alcon, Inc. Preparation d'agents anti-inflammatoires non steroidiens pour traiter l'angiogenese oculaire pathologique
US20050009910A1 (en) * 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
TWI358290B (en) * 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
KR20080011310A (ko) * 2005-05-10 2008-02-01 알콘, 인코퍼레이티드 폴록사머 또는 메록사폴 계면활성제 및 글리콜을유효성분으로 함유하는 현탁제, 안질환 치료용 의약의제조를 위한 그의 용도
PT1906916E (pt) * 2005-05-10 2008-12-10 Alcon Inc Suspensão oftálmica compreendendo um fármaco oftálmico, uma poloxamina e um agente de ajuste da tonicidade de glicol, utilização da referida composição para a produção de um medicamento para o tratamento de distúrbios oftálmicos
US9370444B2 (en) 2010-10-12 2016-06-21 Emmett T. Cunningham, JR. Subconjunctival conformer device and uses thereof
US8915877B2 (en) 2010-10-12 2014-12-23 Emmett T. Cunningham, JR. Glaucoma drainage device and uses thereof
RU2458656C1 (ru) * 2011-06-17 2012-08-20 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения оперированного незакрывшегося макулярного отверстия
EP3013790A1 (fr) 2013-06-27 2016-05-04 Mylan Laboratories Ltd. Procédé pour la préparation de népafénac

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1226344A (fr) 1967-07-31 1971-03-24
SE400966B (sv) 1975-08-13 1978-04-17 Robins Co Inc A H Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror
US4313949A (en) 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
US4254146A (en) * 1979-10-18 1981-03-03 A. H. Robins Company, Inc. 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters
IL61945A (en) * 1980-02-19 1984-09-30 Robins Co Inc A H 2-amino-3-(hydroxy(phenyl)methyl)phenylacetic acids,esters and amides and pharmaceutical compositions containing them
DE3026402A1 (de) * 1980-07-11 1982-02-04 Syntex Corp., Palo Alto, Calif. Die verwendung analgetischer und nicht-hormonaler, entzuendungshemmender mittel bei der behandlung von mikrovaskulaeren erkrankungen
US4503073A (en) * 1981-01-07 1985-03-05 A. H. Robins Company, Incorporated 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids
IL64724A0 (en) * 1981-02-17 1982-03-31 Robins Co Inc A H 2-amino-3-(halobenzoyl)-methylphenylacetic acids and esters and salts thereof and pharmaceutical compositions containing them
US4454151A (en) 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4568695A (en) * 1983-12-07 1986-02-04 A. H. Robins Company, Incorporated 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor
US4851443A (en) 1985-03-14 1989-07-25 Smith Kline Dauelsberg, Gmbh Carboxylic acid amides, compositions and medical use thereof
DE3668450D1 (de) 1985-03-14 1990-03-01 Smithkline Dauelsberg 5-aminosalicylsaeurederivate von nicht-steroidalen entzuendungshemmenden sauren.
US4683242A (en) 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
DK406686D0 (da) 1986-08-26 1986-08-26 Hans Bundgaard Carboxylsyrederivater
CA1325382C (fr) * 1988-01-27 1993-12-21 Takahiro Ogawa Composition therapeutique a administration locale pour les affections inflammatoires
US5314909A (en) 1993-03-17 1994-05-24 Merck & Co., Inc. Use of non-steroidal antiiflammatory agents in macular degeneration
JP3396953B2 (ja) 1994-05-10 2003-04-14 千寿製薬株式会社 網膜疾患予防・治療剤
US5475034A (en) 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
US5643943A (en) * 1994-12-23 1997-07-01 Alcon Laboratories, Inc. Systemic administration of esters and amides of antioxidants which may be used as antioxidant prodrug therapy for oxidative and inflammatory pathogenesis
US5811446A (en) 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US6025353A (en) 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
CN1227008C (zh) 1999-01-07 2005-11-16 范德比尔特大学 将非cox－2选择性抑制剂的cox抑制化合物转化成为cox－2选择性抑制剂的衍生物的方法
US6555540B1 (en) 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
US6426341B1 (en) 1999-06-30 2002-07-30 Pfizer Inc. Treatment for diabetic complications
US6413965B1 (en) 1999-06-30 2002-07-02 Pfizer Inc. Compositions and treatment for diabetic complications
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device

Also Published As

Publication number Publication date
AR030346A1 (es) 2003-08-20
PT1309322E (pt) 2006-11-30
WO2002013805A2 (fr) 2002-02-21
CY1106155T1 (el) 2011-06-08
DK1309322T3 (da) 2006-10-23
DE60120990D1 (de) 2006-08-03
US6638976B2 (en) 2003-10-28
WO2002013805A3 (fr) 2002-05-30
US20020049255A1 (en) 2002-04-25
HK1057332A1 (en) 2004-04-02
CA2418059A1 (fr) 2002-02-21
AU8125801A (en) 2002-02-25
ATE330596T1 (de) 2006-07-15
EP1309322A2 (fr) 2003-05-14
CA2418059C (fr) 2009-12-22
BR0113201A (pt) 2006-05-09
DE60120990T2 (de) 2007-03-15
EP1309322B1 (fr) 2006-06-21
JP2004506010A (ja) 2004-02-26
MXPA03001160A (es) 2004-08-02
ES2266229T3 (es) 2007-03-01

Similar Documents

Publication Publication Date Title
EP2046727B1 (fr) Promédicaments hydrosolubles à charge positive du diclofénac présentant une vitesse de pénétration cutanée très rapide
CA2661649C (fr) Promedicaments hydrosolubles positivement charges d'acetaminophene et de composes associes a vitesse de penetration cutanee tres elevee
JP2012193214A (ja) ベンゾイルフェニル酢酸を使用して、血管形成関連障害を処置するための方法
TWI286933B (en) Method of treating neurodegenerative disorders of the retina and optic nerve head
WO2008044095A1 (fr) Pro-médicaments d'oxicams solubles dans l'eau et chargés positivement et composés apparentés avec une vitesse de pénétration de la peau très élevée
BRPI0818118B1 (pt) Composição farmacêutica na forma de uma suspensão aquosa estabilizada de carisbamato e seu processo de formação
CN103209694A (zh) 用于治疗视网膜疾病的[3-(1-(1h-咪唑-4-基)乙基)-2-甲基苯基]甲醇的酯前药
US20090247638A1 (en) Pharmaceutical use of cox-2-inhibitors in angiogenesis-mediated ocular disorders
AU2001283337A1 (en) Method of treating angiogenesis-related disorders using benzoyl phenylacetic acid
AU2014201024B2 (en) Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate
JP2004506010A5 (fr)
US20030207941A1 (en) Method of treating vascular endothelial growth factor mediated vascular disorders
TW201838629A (zh) 用於預防近視、治療近視及／或預防近視增長之包含蕪地銨作爲活性成分的藥劑
US20040132773A1 (en) Method of treating neurodgenerative disorders of the retina and optic nerve head
AU2001281258A1 (en) Method of treating neurodegenerative disorders of the retina and optic nerve head
AU2016222329A1 (en) Positively charged water-soluble pro-drugs of ibuprofen
AU2006217547A1 (en) Method of treating angiogenesis-related disorders

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees